Clinical Trials Logo

Clinical Trial Summary

Chronic histiocytic intervillositis (CHI) is associated with severe and recurrent obstetrical complications. A link between anti-HLA Antibodies (Ab) and CHI has recently been established. At the Etablissement Français du Sang (EFS), donors who have already given birth once and have high levels of anti-HLA are excluded from donating apheresis platelets and therapeutic plasma to prevent TRALI (Transfusion Related Acute Lung Injury). No studies have examined the obstetrical history of these donors. The question is: is there an association between anti-HLA levels and obstetrical complications?


Clinical Trial Description

Chronic histiocytic intervillositis (CHI) is a rare condition with an incidence of around 5 in 10,000 pregnancies. It is defined by major infiltration of the intervillous cavity by CD68+ maternal histiocytes, associated with fibrin deposition on the villous surface. CHI is associated with severe obstetrical complications and a very high recurrence rate, estimated at between 70% and 100%. These complications include early and late miscarriage, fetal death, severe growth retardation in surviving fetuses, and premature delivery. The survival rate reported in the literature varies between 30% and 50%. Anti-HLA antibodies are present in 54% of pregnant women at the end of pregnancy, and their rate increases towards the end of pregnancy. The presence of HLA antibodies also increases with the number of pregnancies, and is found in up to 74% of cases after more than 2 deliveries. The research question concerns the existence of a statistically significant association between the presence of high levels of anti-HLA antibodies and the occurrence of one or more obstetric complications. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06021925
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Xavier LAFARGE, Doctor
Phone 05 56 90 83 93
Email xavier.lafarge@efs.sante.fr
Status Recruiting
Phase
Start date December 13, 2023
Completion date June 13, 2024

See also
  Status Clinical Trial Phase
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00005721 - Retaining Donors and Increasing Donation Frequency N/A
Recruiting NCT04078893 - The Effect of Recruiting Inactive Blood Donors Using Different Means N/A
Completed NCT02274064 - Motivating Type O- Blood Donors to Return N/A
Completed NCT04783077 - Community-Based Communication Approaches for Blood Donation in Ghana N/A
Completed NCT02717338 - Blood Donor Competence, Autonomy and Relatedness Enhancement Phase 3
Completed NCT01104740 - Dengue Seroprevalence Study in Blood Donors in the French West Indies
Completed NCT03988738 - Promoting Repeat Blood Donation Through Social Media Among First-time Donors in a Peruvian Blood Bank N/A
Completed NCT04088695 - Effect of a Web Page Based on a Motivational Video for Voluntary Blood Donation N/A
Completed NCT00005278 - Retrovirus Epidemiology Donor Study I (REDS I) N/A
Recruiting NCT00001846 - Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Terminated NCT00005341 - Blood Donation--Immune Sequelae and Recruitment
Completed NCT00005339 - Risk of Post Transfusion Hepatitis C Virus Infection N/A
Completed NCT03835299 - Addressing Fear and Risk of Vasovagal Reactions Among High School Donors N/A
Completed NCT00005360 - HIV Diversity and Pathogenesis in Donor-Recipient Clusters N/A
Completed NCT03102385 - A Survey of Attitudes of Experienced Blood Donors N/A
Completed NCT02145507 - Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution Phase 1
Completed NCT00029406 - Transfusion Infections Pediatric Prospective Study (TRIPPS) N/A
Completed NCT00006310 - KSHV Infection in Blood Donors From Texas N/A